Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02113020 | A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects | PHASE1 | COMPLETED | 24 | — | — | Feb 1, 2014 | Sep 1, 2014 | Oct 21, 2014 | 1 | Japan |
| Arm | Type | Description |
|---|---|---|
| TAK-233 | EXPERIMENTAL | Oral administration |
| Placebo | PLACEBO_COMPARATOR | Oral administration |
| Name | Type | Description |
|---|---|---|
| TAK-233 | DRUG | Oral administration of TAK-233 |
| Placebo | DRUG | Oral admininstration of Placebo |
Inclusion Criteria: 1. Subjects who understand the contents of this clinical trial and who the investigator or sub-investigator consider able to comply with the procedures of the clinical trial 2. Subjects who can sign the informed consent form and can date the form without assistance before starti...